Chronic urticaria (CU) is a disease that has a marked effect on patients’ quality of life. Ocular symptoms frequently accompany allergic rhinitis and may therefore be more annoying for the patient than the nasal symptoms themselves. Given that allergic conjunctivitis is accompanied by nasal symptoms, an oral, second-generation H1 antihistamine is the treatment of choice for treating nasal and ocular symptoms simultaneously.
This symposium presents the most relevant aspects of the role of the new antihistamine bilastine in the treatment of patients with allergic rhinoconjunctivitis and chronic urticaria.
